Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.

  • Revenue in USD (TTM)60.11bn
  • Net income in USD365.00m
  • Incorporated1970
  • Employees72.00k
  • Location
    Merck & Co Inc2000 Galloping Hill RoadKENILWORTH 07033United StatesUSA
  • Phone+1 (908) 740-4000
  • Fax+1 (908) 423-1987
  • Websitehttps://www.merck.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MRK:NYQ since
announced
Transaction
value
Caraway Therapeutics IncAnnounced21 Nov 202321 Nov 2023Announced28.31%610.00m
Prometheus Biosciences IncDeal completed16 Apr 202316 Apr 2023Deal completed14.26%10.93bn
Data delayed at least 15 minutes, as of Mar 27 2024 20:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.